Drugs currently in Phase II clinical trials for cocaine addiction

Bibliography

• Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-13
   PubMed Web of Science ®Google Scholar
• Pouletty P. Drug addictions: towards socially accepted and medically treatable diseases. Nat Rev Drug Discov 2002;1:731-6
   PubMed Web of Science ®Google Scholar
• United Nations Office of Drugs and Crime. World Drug Report 2012;134:260-77
   Google Scholar
• Degenhardt L, Bucello C, Calabria B, et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend 2011;117:85-101
   PubMed Web of Science ®Google Scholar
• Ross J. Illicit drug use in Australia: epidemiology, use patterns and associated harm. 2nd edition. National Drug and Alcohol Research Centre; Barton: 2007
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) 1998 – 2008. 2010;1-123
   Google Scholar
• McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-95
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/
   Google Scholar
• Haile CN, Mahoney JJ III, Newton TF, De La Garza R. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther 2012;134:260-77
   PubMed Web of Science ®Google Scholar
• Levey AI, Hersch SM, Rye DB, et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 1993;90:8861-5
   PubMed Web of Science ®Google Scholar
• Eagle DM, Wong JCK, Allan ME, et al. Contrasting roles for dopamine D1 and D2 receptor subtypes in the dorsomedial striatum but not the nucleus accumbens core during behavioral inhibition in the stop-signal task in rats. J Neurosci 2011;31:7349-56
   PubMed Web of Science ®Google Scholar
• Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-8
   PubMed Web of Science ®Google Scholar
• Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159:1642-52
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Volkow N, Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 2005;45:647-50
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wolf AP, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990;147:719-24
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang G-J, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993;14:169-77
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997;386:830-3
   PubMed Web of Science ®Google Scholar
• Martinez D, Broft A, Foltin RW, et al. Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology 2004;29:1190-202
   PubMed Web of Science ®Google Scholar
• Martinez D, Slifstein M, Narendran R, et al. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology 2009;34:1774-82
   PubMed Web of Science ®Google Scholar
• Meador-Woodruff JH, Little KY, Damask SP, et al. Effects of cocaine on dopamine receptor gene expression: a study in the postmortem human brain. Biol Psychiatry 1993;34:348-55
   PubMed Web of Science ®Google Scholar
• Malison RT, Best SE, van Dyck CH, et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] ß-CIT SPECT. Am J Psychiatry 1998;155:832-4
   PubMed Web of Science ®Google Scholar
• Crits-Christoph P, Newberg A, Wintering N, et al. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend 2008;98:70-6
   PubMed Web of Science ®Google Scholar
• Wang G-J, Volkow ND, Fowler JS, et al. Cocaine abusers do not show loss of dopamine transporters with age. Life Sci 1997;61:1059-65
   PubMed Web of Science ®Google Scholar
• Narendran R, Lopresti BJ, Martinez D, et al. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 2012;169:55-63
   PubMed Web of Science ®Google Scholar
• Little KY, Krolewski DM, Zhang L, Cassin BJ. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 2003;160:47-55
   PubMed Web of Science ®Google Scholar
• Wilson JM, Shannak K, Kish SJ, et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996;40:428-39
   PubMed Web of Science ®Google Scholar
• Kish SJ, Robitaille Y, El-Awar M, et al. Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 1992;42:1573-
   PubMed Web of Science ®Google Scholar
• Teneud LM, Baptista T, Murzi E, et al. Systemic and local cocaine increase extracellular serotonin in the nucleus accumbens. Pharmacol Biochem Behav 1996;53:747-52
   PubMed Web of Science ®Google Scholar
• Jacobsen LK, Staley JK, Malison RT, et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 2000;157:1134-40
   PubMed Web of Science ®Google Scholar
• Little KY, Patel UN, Clark TB, Butts JD. Alteration of brain dopamine and serotonin levels in cocaine users: a preliminary report. Am J Psychiatry 1996;153:1216-18
   PubMed Web of Science ®Google Scholar
• Matuskey D, Bhagwagar Z, Planeta B, et al. Reductions in brain 5-HT1B receptor availability in primarily cocaine-dependent humans. Biol Psychiatry 2014; In press
   PubMed Web of Science ®Google Scholar
• Ke Y, Streeter CC, Nassar LE, et al. Frontal lobe GABA levels in cocaine dependence: a two-dimensional, J-resolved magnetic resonance spectroscopy study. Psychiatry Res Neuroimaging 2004;130:283-93
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Volkow ND. New medications for drug addiction hiding inglutamatergic neuroplasticity. Mol Psychiatry 2011;16:974-86
   PubMed Web of Science ®Google Scholar
• Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31-9
   PubMed Web of Science ®Google Scholar
• Royer S, Pare D. Conservation of total synaptic weight through balanced synaptic depression and potentiation. Nature 2003;422:518-22
   PubMed Web of Science ®Google Scholar
• Stuber GD, Hnasko TS, Britt JP, et al. Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. J Neurosci 2010;30:8229-33
   PubMed Web of Science ®Google Scholar
• Yang S, Salmeron BJ, Ross TJ, et al. Lower glutamate levels in rostral anterior cingulate of chronic cocaine users — A 1H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy. Psychiatry Res Neuroimaging 2009;174:171-6
   PubMed Web of Science ®Google Scholar
• Li S-J, Wang Y, Pankiewicz J, Stein EA. Neurochemical adaptation to cocaine abuse: reduction of N-acetyl aspartate in thalamus of human cocaine abusers. Biol Psychiatry 1999;45:1481-7
   PubMed Web of Science ®Google Scholar
• Hetherington HP, Pan JW, Telang F, et al. Reduced brain GABA levels in cocaine abusers. Proc Intern Soc Magn Reson Med 2000;523
   Google Scholar
• Kreek MJ, Bart G, Lilly C, et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005;57:1-26
   PubMed Web of Science ®Google Scholar
• Jay TM. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 2003;69:375-90
   PubMed Web of Science ®Google Scholar
• Zolkowska D, Jain R, Rothman RB, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 2009;329:738-46
   PubMed Web of Science ®Google Scholar
• Murillo-Rodríguez E, Haro R, Palomero-Rivero M, et al. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007;176:353-7
   PubMed Web of Science ®Google Scholar
• Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006;319:561-9
   PubMed Web of Science ®Google Scholar
• Dopheide MM, Morgan RE, Rodvelt KR, et al. Modafinil evokes striatal [3H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007;568:112-23
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2007;33:1477-502
   PubMed Web of Science ®Google Scholar
• Korotkova TM, Klyuch BP, Ponomarenko AA, et al. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007;52:626-33
   PubMed Web of Science ®Google Scholar
• Nelson AB, Hang GB, Grueter BA, et al. A comparison of striatal-dependent behaviors in wild-type and hemizygous Drd1a and Drd2 BAC transgenic mice. J Neurosci 2012;32:9119-23
   PubMed Web of Science ®Google Scholar
• Ball KT, Combs TA, Beyer DN. Opposing roles for dopamine D1- and D2-like receptors in discrete cue-induced reinstatement of food seeking. Behav Brain Res 2011;222:390-3
   PubMed Web of Science ®Google Scholar
• Ferraro L, Fuxe K, Tanganelli S, et al. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000;39:1974-83
   PubMed Web of Science ®Google Scholar
• Ferraro L, Antonelli T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999;20:346-56
   PubMed Web of Science ®Google Scholar
• Wong YN, King SP, Simcoe D, et al. Open-label, single-dose Pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999;39:281-8
   PubMed Web of Science ®Google Scholar
• Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60
   PubMed Web of Science ®Google Scholar
• Donovan JL, DeVane CL, Malcolm RJ, et al. Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. Clin Pharmacokinet 2005;44:753-65
   PubMed Web of Science ®Google Scholar
• Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003;70:29-37
   PubMed Web of Science ®Google Scholar
• Malcolm R, Swayngim K, Donovan JL, et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006;32:577-87
   PubMed Web of Science ®Google Scholar
• Hart CL, Haney M, Vosburg SK, et al. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008;33:761-8
   PubMed Web of Science ®Google Scholar
• Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-11
   PubMed Web of Science ®Google Scholar
• Anderson AL, Reid MS, Li S-H, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009;104:133-9
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Green CE, Stotts AL, et al. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa–carbidopa, naltrexone. Drug Alcohol Depend 2014;136:100-7
   PubMed Web of Science ®Google Scholar
• Baranski JV, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol Clin Exp 2004;19:323-32
   PubMed Web of Science ®Google Scholar
• Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003;165:260-9
   PubMed Web of Science ®Google Scholar
• Kalechstein AD, Mahoney JJ III, Yoon JH, et al. Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. Neuropharmacology 2013;64:472-8
   PubMed Web of Science ®Google Scholar
• Moeller FG, Steinberg JL, Schmitz JM, et al. Working memory fMRI activation in cocaine-dependent subjects: association with treatment response. Psychiatry Res Neuroimaging 2010;181:174-82
   PubMed Web of Science ®Google Scholar
• Ma L, Steinberg JL, Hasan KM, et al. Stochastic dynamic causal modeling of working memory connections in cocaine dependence. Hum Brain Mapp 2012;35:760-78
   PubMed Web of Science ®Google Scholar
• Winhusen TM, Somoza EC, Lewis DF, et al. Frontal systems deficits in stimulant-dependent patients: evidence of pre-illness dysfunction and relationship to treatment response. Drug Alcohol Depend 2013;127:94-100
   PubMed Web of Science ®Google Scholar
• Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 2010;116:164-76
   Web of Science ®Google Scholar
• Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007;47:681-98
   PubMed Web of Science ®Google Scholar
• Stoops WW, Glaser PE, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 2004;18:534-43
   PubMed Web of Science ®Google Scholar
• Rush CR, Stoops WW, Hays LR. Cocaine effects during d-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend 2009;99:261-71
   PubMed Web of Science ®Google Scholar
• Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:21-31
   PubMed Web of Science ®Google Scholar
• Rush CR, Stoops WW, Sevak RJ, Hays LR. Cocaine choice in humans during D-amphetamine maintenance. J Clin Pharmacol 2010;30:152-9
   Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29:969-81
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Pharmacol 2001;21:522-6
   Web of Science ®Google Scholar
• Shearer J, Wodak A, van Beek I, et al. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003;98:1137-41
   PubMed Web of Science ®Google Scholar
• Castells X, Casas M, Vidal X, et al. Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. Addiction 2007;102:1871-87
   PubMed Web of Science ®Google Scholar
• Pérez-Mañá C, Castells X, Vidal X, et al. Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials. J Subst Abuse Treat 2011;40:109-22
   PubMed Web of Science ®Google Scholar
• Rosen H, Flemenbaum A, Slater VL. Clinical trial of carbidopa-{l}-dopa combination for cocaine abuse. Am J Psychiatry 1986;143:1493
   PubMed Web of Science ®Google Scholar
• Wolfsohn R, Angrist B. A pilot trial of levodopa/carbidopa in early cocaine abstinence. J Clin Pharmacol 1990;10:440-2
   Web of Science ®Google Scholar
• Wolfsohn R, Sanfilipo M, Augrist B. A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence. Neuropsychopharmacology 1993;9:49-53
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Watson DW, Reiber C, et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 2005;100:78-90
   PubMed Web of Science ®Google Scholar
• Mooney ME, Schmitz JM, Moeller FG, Grabowski J. Safety, tolerability and efficacy of levodopa–carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007;88:214-23
   PubMed Web of Science ®Google Scholar
• Meini M, Capovani B, Sbrana A, et al. A pilot open-label trial of ropinirole for cocaine dependence. Am J Addict 2008;17:165-6
   PubMed Web of Science ®Google Scholar
• Meini M, Moncini M, Cecconi D, et al. Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study. Curr Pharm Des 2011;17:1376-83
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Mooney ME, Moeller FG, et al. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend 2008;94:142-50
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Lindsay JA, Stotts AL, et al. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp Clin Psychopharmacol 2010;18:238-44
   PubMed Web of Science ®Google Scholar
• Stanley WC, Li B, Bonhaus DW, et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 1997;121:1803-9
   PubMed Web of Science ®Google Scholar
• Devoto P, Flore G, Saba P, et al. The dopamine beta-hydroxylase inhibitor nepicastat increases dopamine release and potentiates psychostimulant-induced dopamine release in the prefrontal cortex. Addict Biol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Manvich DF, DePoy LM, Weinshenker D. Dopamine beta-hydroxylase inhibitors enhance the discriminative stimulus effects of cocaine in rats. J Pharmacol Exp Ther 2013;347:564-73
   PubMed Web of Science ®Google Scholar
• Gaval-Cruz M, Liles LC, Iuvone PM, Weinshenker D. Chronic inhibition of dopamine beta-hydroxylase facilitates behavioral responses to cocaine in mice. PLoS One 2012;7:e50583
   PubMed Web of Science ®Google Scholar
• Schroeder JP, Epps SA, Grice TW, Weinshenker D. The selective dopamine beta-hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaine-seeking behavior. Neuropsychopharmacology 2013;38:1032-8
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649-66
   PubMed Web of Science ®Google Scholar
• Brown ES, Jeffress J, Liggin JD, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005;66:756-60
   PubMed Web of Science ®Google Scholar
• Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005;25:363-6
   PubMed Web of Science ®Google Scholar
• Stoops WW, Lile JA, Lofwall MR, Rush CR. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse 2007;33:769-76
   PubMed Web of Science ®Google Scholar
• Lile JA, Stoops WW, Hays LR, Rush CR. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Am J Drug Alcohol Abuse 2008;34:721-9
   PubMed Web of Science ®Google Scholar
• Vorspan F, Bellais L, Keijzer L, Lépine JP. An open-label study of aripiprazole in nonschizophrenic crack-dependent patients. J Clin Psychopharmacol 2008;28:570-2
   PubMed Web of Science ®Google Scholar
• Haney M, Rubin E, Foltin RW. Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacology (Berl) 2011;216:379-87
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Nuzzo PA, Campbell C, Walsh SL. Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Exp Clin Psychopharmacol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lile JA, Stoops WW, Glaser PE, et al. Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. J Psychopharmacol 2011;25:1469-79
   PubMed Web of Science ®Google Scholar
• Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT 1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997;16:333-8
   PubMed Web of Science ®Google Scholar
• Jadhav SA, Gaikwad RV, Gaonkar RK, et al. Dose-dependent response of central dopaminergic systems to buspirone in mice. Indian J Exp Biol 2008;46:704
   PubMed Web of Science ®Google Scholar
• Bergman J, Roof RA, Furman CA, et al. Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors. Int J Neuropsychopharmacol 2013;16:445-58
   PubMed Web of Science ®Google Scholar
• Shelton KL, Hendrick ES, Beardsley PM. Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats. Drug Alcohol Depend 2013;129:210-16
   PubMed Web of Science ®Google Scholar
• Giannini AJ, Loiselle RH, Graham BH, Folts DJ. Behavioral response to buspirone in cocaine and phencyclidine withdrawal. J Subst Abuse Treat 1993;10:523-7
   PubMed Web of Science ®Google Scholar
• Moeller FG, Dougherty DM, Barratt ES, et al. The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat 2001;21:193-8
   PubMed Web of Science ®Google Scholar
• Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004;12:305-20
   PubMed Web of Science ®Google Scholar
• Johnson BA, Roache JD, Ait-Daoud N, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006;84:256-63
   PubMed Web of Science ®Google Scholar
• Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol 2002;7:357-64
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with [11C] raclopride. Neuropsychopharmacology 1999;20:424-33
   PubMed Web of Science ®Google Scholar
• Latini G, Verrotti A, Manco R, et al. Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev Med Chem 2008;8:10-23
   PubMed Web of Science ®Google Scholar
• Johnson BA, Roache JD, Ait-Daoud N, et al. Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking. Addict Biol 2012;18:405-16
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004;75:233-40
   PubMed Web of Science ®Google Scholar
• Kadden R, Carroll K, Donovan D, et al. Cognitive-behavioral coping skills therapy manual: a clinical research guide for treating individuals with alcohol abuse and dependence. National Institute on Alcohol Abuse and Alcoholism, Rockville, MD; 1994
   Google Scholar
• Johnson BA, Ait-Daoud N, Wang X-Q, et al. Topiramate for the treatment of cocaine addiction. JAMA Psychiatry 2013;70:1338
   PubMed Web of Science ®Google Scholar
• Reis AD, Castro LA, Faria R, Laranjeira R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 2008;30:132-5
   PubMed Web of Science ®Google Scholar
• Harris JA, Westbrook RF. Evidence that GABA transmission mediates context-specific extinction of learned fear. Psychopharmacology 1998;140:105-15
   PubMed Web of Science ®Google Scholar
• Chhatwal JP, Myers KM, Ressler KJ, Davis M. Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction. J Neurosci 2005;25:502-6
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Pavlicova M, Bisaga A, et al. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012;72:950-6
   PubMed Web of Science ®Google Scholar
• Lal R, Sukbuntherng J, Tai EH, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009;330:911-21
   PubMed Web of Science ®Google Scholar
• Ong J, Kerr DI. Clinical potential of GABAB receptor modulators. CNS Drug Rev 2005;11:317-34
   PubMedGoogle Scholar
• Franchitto N, Pelissier F, Lauque D, et al. Self-intoxication with Baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol 2014;49:79-83
   PubMed Web of Science ®Google Scholar
• Lile JA, Stoops WW, Allen TS, et al. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology (Berl) 2004;171:441-9
   PubMed Web of Science ®Google Scholar
• Haney M, Hart CL, Foltin RW. Effects of baclofen on cocaine self-administration: opioid-and nonopioid-dependent volunteers. Neuropsychopharmacology 2006;31:1814-21
   PubMed Web of Science ®Google Scholar
• Rotheram-Fuller E, La Garza De R II, Mahoney JJ III, et al. Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. Psychiatry Res 2007;152:205-10
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003;64:1440-8
   PubMed Web of Science ®Google Scholar
• Kahn R, Biswas K, Childress A-R, et al. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend 2009;103:59-64
   PubMed Web of Science ®Google Scholar
• Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982;71:539-42
   PubMed Web of Science ®Google Scholar
• Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamlne, part two: a review of problem use and dependence. J Psychoactive Drugs 2001;33:151-8
   PubMed Web of Science ®Google Scholar
• Lankenau SE, Bloom JJ, Shin C. Longitudinal trajectories of ketamine use among young injection drug users. Int J Drug Policy 2010;21:306-14
   PubMed Web of Science ®Google Scholar
• Olthuis JV, Darredeau C, Barrett SP. Substance use initiation: the role of simultaneous polysubstance use. Drug Alcohol Rev 2013;32:67-71
   PubMed Web of Science ®Google Scholar
• Abdel Rahman MS, Ismail EE. Teratogenic effect of ketamine and cocaine in CF-1 mice. Teratology 2000;61:291-6
   PubMedGoogle Scholar
• Murphy JL. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth 1993;40:160-4
   PubMed Web of Science ®Google Scholar
• Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013;4:161
   PubMed Web of Science ®Google Scholar
• Pandit SK, Dundee JW, Bovill JG. Clinical studies of induction agents XXXVII: amnesic action of ketamine. Br J Anaesth 1971;43:362-4
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Perry EB, Cho H-S, et al. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology (Berl) 2006;187:405-14
   PubMed Web of Science ®Google Scholar
• Albright JA, Stevens SA, Beussman DJ. Detecting ketamine in beverage residues: application in date rape detection. Drug Test Anal 2011;4:337-41
   PubMed Web of Science ®Google Scholar
• Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 1990;345:716-18
   PubMed Web of Science ®Google Scholar
• Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993;16:73-93
   PubMed Web of Science ®Google Scholar
• Horne MK, Lee J, Chen F, et al. Long term administration of cocaine or serotonin reuptake inhibitors results in anatomical and neurochemical changes in noradrenergic, dopaminergic and serotonin pathways. J Neurochem 2008;106:1731-44
   PubMed Web of Science ®Google Scholar
• Holman BL, Carvalho PA, Mendelson J, et al. Brain perfusion is abnormal in cocaine-dependent polydrug users: a study using technetium-99m-HMPAO and ASPECT. J Nucl Med 1991;32:1206-10
   PubMed Web of Science ®Google Scholar
• Elliott HL, Meredith PA, Sumner DJ, et al. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol 1982;13:699-703
   PubMed Web of Science ®Google Scholar
• Newton TF, La Garza De R II, Brown G, et al. Noradrenergic α1 receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS One 2012;7:e30854
   PubMed Web of Science ®Google Scholar
• Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug Alcohol Depend 2013;131:66-70
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Brown S, Babb DA, et al. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend 2000;60:69-76
   PubMed Web of Science ®Google Scholar
• Self T, Rogers ML, Mancell J, Soberman JE. Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma. Am J Med Sci 2011;342:56-61
   PubMed Web of Science ®Google Scholar
• Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001;63:69-78
   PubMed Web of Science ®Google Scholar
• Kampman KM, Dackis C, Lynch KG, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006;85:129-37
   PubMed Web of Science ®Google Scholar
• Ahmadi J, Kampman K, Dackis C. Outcome predictors in cocaine dependence treatment trials. Am J Addict 2006;15:434-9
   PubMed Web of Science ®Google Scholar
• Misanin JR, Miller RR, Lewis DJ. Retrograde amnesia produced by electroconvulsive shock after reactivation of a consolidated memory trace. Science 1968;160:554-5
   PubMed Web of Science ®Google Scholar
• Milton AL, Lee JLC, Everitt BJ. Reconsolidation of appetitive memories for both natural and drug reinforcement is dependent on -adrenergic receptors. Learn Mem 2008;15:88-92
   PubMed Web of Science ®Google Scholar
• Przybyslawski J, Roullet P, Sara SJ. Attenuation of emotional and nonemotional memories after their reactivation: role of beta adrenergic receptors. J Neurosci 1999;19:6623-8
   PubMed Web of Science ®Google Scholar
• Diergaarde L, Schoffelmeer ANM, De Vries TJ. Beta-adrenoceptor mediated inhibition of long-term reward-related memory reconsolidation. Behav Brain Res 2006;170:333-6
   PubMed Web of Science ®Google Scholar
• Dudai Y. Reconsolidation: the advantage of being refocused. Curr Opin Neurobiol 2006;16:174-8
   PubMed Web of Science ®Google Scholar
• Brunet A, Poundja J, Tremblay J, et al. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. J Clin Psychopharmacol 2011;31:547-50
   PubMed Web of Science ®Google Scholar
• Saladin ME, Gray KM, McRae-Clark AL, et al. A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology (Berl) 2013;226:721-37
   PubMed Web of Science ®Google Scholar
• Evrard I, Legleye S, Cadet-Taïrou A. Composition, purity and perceived quality of street cocaine in France. Int J Drug Policy 2010;21:399-406
   PubMed Web of Science ®Google Scholar
• Tzeng W-Y, Chang W-T, Chuang J-Y, et al. Disruption of memory reconsolidation impairs storage of other, non-reactivated memory. Neurobiol Learn Mem 2012;97:241-9
   PubMed Web of Science ®Google Scholar
• Chang S-D, Chen D-Y, Liang KC. Infusion of lidocaine into the dorsal hippocampus before or after the shock training phase impaired conditioned freezing in a two-phase training task of contextual fear conditioning. Neurobiol Learn Mem 2008;89:95-105
   PubMed Web of Science ®Google Scholar
• Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv 2013;51:11-14
   Web of Science ®Google Scholar
• Fagen ZM, Mitchum R, Vezina P, McGehee DS. Enhanced nicotinic receptor function and drug abuse vulnerability. J Neurosci 2007;27:8771-8
   PubMed Web of Science ®Google Scholar
• Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 2003;37:577-82
   PubMed Web of Science ®Google Scholar
• Graf EN, Wheeler RA, Baker DA, et al. Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. J Neurosci 2013;33:11800-10
   PubMed Web of Science ®Google Scholar
• Patkar AA, Mannelli P, Hill KP, et al. Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. Hum Psychopharmacol Clin Exp 2006;21:367-75
   PubMed Web of Science ®Google Scholar
• Gorelick DA, Simmons MS, Carriero N, Tashkin DP. Characteristics of smoked drug use among cocaine smokers. Am J Addict 1997;6:237-45
   PubMed Web of Science ®Google Scholar
• Crunelle CL, Miller ML, Booij J, van den Brink W. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol 2010;20:69-79
   PubMed Web of Science ®Google Scholar
• Poling J, Rounsaville B, Gonsai K, et al. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict 2010;19:401-8
   PubMed Web of Science ®Google Scholar
• Plebani JG, Lynch KG, Yu Q, et al. Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend 2012;121:163-6
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-66
   PubMed Web of Science ®Google Scholar
• Jenkins TA, Allen AM, Chai SY, et al. Interactions of angiotensin II with central dopamine. Adv Exp Med Biol 1996;396:93-103
   PubMedGoogle Scholar
• Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002;20:1196-204
   PubMed Web of Science ®Google Scholar
• Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58:158-64
   PubMed Web of Science ®Google Scholar
• Haney M, Gunderson EW, Jiang H, et al. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010;67:59-65
   PubMed Web of Science ®Google Scholar
• Orson FM, Rossen RD, Shen X, et al. Spontaneous development of IgM anti‐cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict 2013;22:169-74
   PubMed Web of Science ®Google Scholar
• Stoops WW, Blackburn JW, Hudson DA, et al. Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance. Drug Alcohol Depend 2008;92:282-5
   PubMed Web of Science ®Google Scholar
• Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005;8:1445-9
   PubMed Web of Science ®Google Scholar
• Bergman J. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D2 partial agonist aripiprazole (Abilify®). Exp Clin Psychopharmacol 2008;16:475-83
   PubMed Web of Science ®Google Scholar
• Gorelick DA, Kim YK, Bencherif B, et al. Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl) 2008;200:475-86
   PubMed Web of Science ®Google Scholar
• McClure EA, Gipson CD, Malcolm RJ, et al. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs 2014;28:95-106
   PubMed Web of Science ®Google Scholar